為達最佳瀏覽效果,建議使用 Chrome、Firefox 或 Microsoft Edge 的瀏覽器。

請至Edge官網下載 請至FireFox官網下載 請至Google官網下載
晴時多雲

限制級
您即將進入之新聞內容 需滿18歲 方可瀏覽。
根據「電腦網路內容分級處理辦法」修正條文第六條第三款規定,已於網站首頁或各該限制級網頁,依台灣網站分級推廣基金會規定作標示。 台灣網站分級推廣基金會(TICRF)網站:http://www.ticrf.org.tw

《TAIPEI TIMES》 Team makes cancer breakthrough

Jou Yuh-shan, right, a research fellow at Academia Sinica’s Institute of Biomedical Sciences, and postdoctoral researcher Yeh Hsi-wen yesterday participate in a news conference in Taipei to introduce the findings of their study on cancer metastatasis related to a gene named paraspeckle component 1.
Photo: Wu Liang-yi, Taipei Times

Jou Yuh-shan, right, a research fellow at Academia Sinica’s Institute of Biomedical Sciences, and postdoctoral researcher Yeh Hsi-wen yesterday participate in a news conference in Taipei to introduce the findings of their study on cancer metastatasis related to a gene named paraspeckle component 1. Photo: Wu Liang-yi, Taipei Times

2018/05/03 03:00

By Jonathan Chin / Staff writer, with CNA

Taiwanese researchers have become the first in the world to pin down a gene key to triggering metastasis of cancer cells, scientists at Academia Sinica announced yesterday.

The gene, known as paraspeckle component 1 — or PSPC1 — causes the metastasis of cancer in 60 percent to 70 percent of human patients, Jou Yuh-shan (周玉山), a research fellow at Academia Sinica’s Institute of Biomedical Sciences, told a news conference in Taipei.

In early-stage cancer, the condition affects only a localized part of the body, but when cancer spreads, the diagnosis changes to stage three or stage four, signifying that cancer cells are growing and spreading through blood vessels, he said.

Stage three and stage four cancer is marked by the progression of cancer into other parts of the body, resulting in a deterioration of health and eventual death, he said.

After a decade of research, his team has identified PSPC1 as the gene that plays a crucial role in metastasis and controls the functions of other genes in cancer cells, such as inhibiting apoptosis, or natural cell death, he said.

Large-scale expression of PSPC1 is present in 60 percent to 70 percent of late-stage cancers, including breast, liver, lung and prostate cancers, he said.

PSPC1 not only augments the generation of cancer cells, but it also enables metastasis by imparting mobility and stem-cell like characteristics to normal cells, resulting in a superior growth rate and the drug resistance of cancer cells, he said.

Furthermore, the gene alters the cell’s cytokines to produce growth factor beta 1, also known as TGF-beta 1, which regulates apoptosis, he said.

In its altered state, the factor instead prolongs the lifespan and reproduction of cancer cells, he said.

The rate of PSPC1 expression is exceedingly low in healthy human beings, while high rates of its expression correspond with cancer that is reproducing and metastasizing, he said.

“In elucidating PSCS1 functionality and TGF-beta 1 behavior in metastasizing cancer, this research represents a major breakthrough,” Jou said.

The team’s study was published in the journal Nature Cell Biology on March 28.

The research team has identified an inhibitor of PSPC1 that has potential medical value, but its development for actual application in cancer treatment could take between 10 and 20 years, he said.

新聞來源:TAIPEI TIMES

不用抽 不用搶 現在用APP看新聞 保證天天中獎  點我下載APP  按我看活動辦法

焦點今日熱門

2024巴黎奧運

看更多!請加入自由時報粉絲團

網友回應

載入中
此網頁已閒置超過5分鐘,請點擊透明黑底或右下角 X 鈕。